The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Erlotinib after initial platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small cell lung cancer (NSCLC): Results of a combined patient-level analysis of the BR.21 and SATURN trials.
Raymond U Osarogiagbon
Consultant or Advisory Role - Astellas Pharma; Pfizer; Roche
Honoraria - Astellas Pharma; Pfizer; Roche
Federico Cappuzzo
Consultant or Advisory Role - Roche (U)
Tudor-Eliade Ciuleanu
Consultant or Advisory Role - OSI Pharmaceuticals; Roche
Honoraria - OSI Pharmaceuticals; Roche
Larry Leon
Employment or Leadership Position - Genentech
Stock Ownership - Genentech